Cargando…
Thalidomide for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Clinical Trial
BACKGROUND: Coronavirus disease 2019 has become a public health concern with a high number of fatalities. Thalidomide can target inflammatory mediators and decrease inflammation in SARS-CoV-2. MATERIALS AND METHODS: An open-label, randomized controlled trial was conducted on patients with compatible...
Autores principales: | Amra, Babak, Ashrafi, Farzaneh, Torki, Mehdi, Hashemi, Marzieh, Shirzadi, Mohamad, Soltaninejad, Forogh, Sadeghi, Somayeh, Salmasi, Mehrzad, Sami, Ramin, Darakhshandeh, Ali, Nasirian, Maryam, Pourajam, Samaneh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012021/ https://www.ncbi.nlm.nih.gov/pubmed/36926422 http://dx.doi.org/10.4103/abr.abr_248_21 |
Ejemplares similares
-
Cardiac involvement according to echocardiographic findings in severe coronavirus disease 2019
por: Tajmirriahi, Marzieh, et al.
Publicado: (2021) -
Healthcare workers’ sleep and mood disturbances during COVID-19 outbreak in an Iranian referral center
por: Amra, Babak, et al.
Publicado: (2021) -
Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
por: Vaezi, Atefeh, et al.
Publicado: (2023) -
Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
por: Amra, Babak, et al.
Publicado: (2023) -
Secondary Bacterial Infection and Clinical Characteristics in Patients With COVID-19 Admitted to Two Intensive Care Units of an Academic Hospital in Iran During the First Wave of the Pandemic
por: Pourajam, Samaneh, et al.
Publicado: (2022)